Reviewed by MedNext Clinical Team
Salbutamol (albuterol in North America) is a short-acting beta-2 adrenoceptor agonist (SABA) and the most widely prescribed reliever inhaler for asthma and chronic obstructive pulmonary disease (COPD). Its rapid bronchodilator effect — onset within 5 minutes, peak at 30–60 minutes, duration 3–5 hours — makes it the cornerstone of acute symptom relief. However, overreliance on salbutamol is a marker of poorly controlled asthma and carries its own risks [1].
Mechanism of Action
Salbutamol selectively activates beta-2 adrenoceptors on airway smooth muscle, activating adenylyl cyclase, raising intracellular cyclic AMP, activating protein kinase A, and ultimately causing smooth muscle relaxation and bronchodilation. At therapeutic inhaled doses, beta-1 cardiac receptor activation is minimal, though systemic absorption — particularly with high doses via nebuliser — produces dose-dependent cardiovascular effects.
Inhaler Technique
Poor inhaler technique is the single most common cause of suboptimal asthma control. Studies consistently show that over 70% of patients demonstrate at least one critical error in inhaler technique, and that correct technique is rarely achieved without formal education and demonstration. Key steps for a pressurised metered-dose inhaler (pMDI) are: shake well; breathe out fully; form a seal around the mouthpiece; press the canister and breathe in slowly and deeply simultaneously; hold the breath for 10 seconds; wait 30–60 seconds before a second puff. A spacer device substantially improves lung deposition and should be used routinely for pMDIs, particularly for children and patients who struggle to coordinate actuation and inhalation [1].
Dosing
For acute symptom relief in adults and children over 5 years: 100–200 micrograms (1–2 puffs) as needed, up to four times daily. During acute exacerbations, higher doses — 2.5–5 mg via nebuliser or 4–10 puffs via pMDI with spacer — may be required. The frequency of salbutamol use is a key monitoring indicator: requiring salbutamol more than twice a week (excluding prevention of exercise-induced bronchoconstriction) indicates inadequate asthma control and should prompt review of preventer therapy [1].
Overreliance and Asthma Control
The Global Initiative for Asthma (GINA) strategy document has emphasised for over a decade that SABA-only treatment — without an inhaled corticosteroid (ICS) — is associated with increased risk of severe asthma exacerbations and asthma-related death. Dispensing of three or more salbutamol inhalers in a 12-month period is an indicator of at-risk patients who should be reviewed. GINA now recommends that all patients with asthma receive ICS-containing therapy as their preferred preventer, with SABA reserved for acute symptom relief rather than regular scheduled dosing [1].
Adverse Effects
At standard inhaled doses, adverse effects are minimal. Dose-dependent effects include fine tremor (the most common complaint, due to skeletal muscle beta-2 stimulation), palpitations, and mild tachycardia. Hypokalaemia is a clinically significant adverse effect at high doses (via beta-2-mediated intracellular potassium shift) — particularly relevant during acute severe asthma when patients receive repeated high-dose nebulised salbutamol alongside systemic corticosteroids and theophylline. Serum potassium should be monitored during intensive SABA therapy.
References
- Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2022 for asthma management and prevention. Eur Respir J. 2022;59(1):2101601.